In a significant move to strengthen its presence in key therapy areas, Pfizer India has partnered with Cipla to market and distribute four of its legacy brands in India, including the popular Corex cough syrups.
Exclusive Agreement Details
The agreement gives Cipla the sole rights to sell and distribute two Corex variants, Dx and LS, along with Dolonex (an NSAID), Neksium (a proton pump inhibitor), and Dalacin C (an oral antibiotic). Pfizer will continue to manufacture and supply the products, while Cipla will leverage its deep distribution network to meet the needs of millions of patients.
Key Terms of the Deal
The agreement is for a five-year period, with no upfront consideration. The financial terms of the deal have not been disclosed. This partnership marks the first collaboration between the two pharma giants in India, where Pfizer has operated for over 75 years.
Benefits for Both Parties
According to Meenakshi Nevatia, Country President at Pfizer India, “this partnership combines Pfizer’s innovation with Cipla’s deep distribution network to meet the needs of millions of patients”. Cipla COO Achin Gupta called the tie-up a step toward “making strong brands even stronger”. The alliance is expected to reinforce Cipla’s footprint across respiratory and gastrointestinal segments.
Expected Outcomes
Some of the key expectations from this deal include:
- Increased sales of Corex cough syrups and other legacy brands
- Strengthened presence of Pfizer in key therapy areas
- Expanded distribution network for Pfizer products through Cipla’s channels
- Reinforced footprint of Cipla in respiratory and gastrointestinal segments
Remember, this is a business development, not a prediction of future performance. It’s essential to do your own research and consider multiple sources before making any investment decisions.